Nearly two-thirds of foreign drug manufacturers and 38.9 percent of domestic facilities failed to submit FARs during the four-year period, the FDA’s Office of Pharmaceutical Quality found.
Although most of the sites handled non-sterile products, the missing FAR reports can include anything from a mislabeled batch to bacterial contamination.
The report did not specify which facilities failed to alert the FDA about potential safety problems.
